ProKidney (PROK) Projected to Post Earnings on Monday

ProKidney (NASDAQ:PROK) will likely be releasing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $0.0010 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 12:30 PM ET.

ProKidney Trading Down 2.1%

Shares of PROK opened at $2.30 on Monday. The firm has a market cap of $691.91 million, a PE ratio of -4.18 and a beta of 1.75. ProKidney has a 12 month low of $0.46 and a 12 month high of $7.13. The stock has a fifty day moving average price of $2.16 and a 200-day moving average price of $2.44.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on PROK shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProKidney in a research note on Thursday, January 22nd. HC Wainwright started coverage on ProKidney in a research note on Tuesday, December 16th. They set a “buy” rating and a $12.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $7.40.

Hedge Funds Weigh In On ProKidney

Several hedge funds and other institutional investors have recently bought and sold shares of PROK. Millennium Management LLC acquired a new stake in ProKidney during the 3rd quarter valued at approximately $4,734,000. JPMorgan Chase & Co. boosted its holdings in ProKidney by 3,024.9% in the second quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company’s stock valued at $988,000 after purchasing an additional 1,615,243 shares during the last quarter. Renaissance Technologies LLC grew its position in ProKidney by 578.6% during the 4th quarter. Renaissance Technologies LLC now owns 895,705 shares of the company’s stock worth $2,006,000 after purchasing an additional 763,705 shares during the period. Jane Street Group LLC purchased a new position in shares of ProKidney during the 2nd quarter valued at about $350,000. Finally, Marshall Wace LLP lifted its holdings in shares of ProKidney by 654.2% in the 4th quarter. Marshall Wace LLP now owns 612,485 shares of the company’s stock valued at $1,372,000 after buying an additional 531,279 shares during the period. Institutional investors and hedge funds own 51.59% of the company’s stock.

ProKidney Company Profile

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.